Stock futures signal firmer start for Wall St Oct 7, 2009
Impax Laboratories Inc (IPXL.O) will be able to sell a generic version of Astellas Pharma's (4503. T) Flomax prostate drug one month ahead of its U.S. patent expiry under a settlement agreement. (Yahoo News -- Press Releases)
Semi-Annual Changes to the NASDAQ Biotechnology Index May 9, 2009
Impax Laboratories, Inc. (NasdaqGM: - ) develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The Company specializes in the development of niche and controlled release generics, as well as the development of branded products. (Primezone Releases)
NASDAQ OMX Announces First Quarter 2009 New Listings Statistics Apr 16, 2009
Other notable listings included specialty pharmaceutical company Impax Laboratories Inc. (NasdaqGM: - ) and SmartHeat (NasdaqGM: - ), a Chinese manufacturer of plate heat exchangers. To view all new listings on The NASDAQ Stock Market in the first quarter, visit. (Primezone Releases)
Warner Chilcott Announces Receipt of FDA Response to Citizen Petition Mar 18, 2009
In its response, the FDA noted that "under current law, a 30-month stay will apply to an ANDA referencing an old antibiotic if that ANDA contains a paragraph IV certification to a patent submitted to the [FDA] before the ANDA was submitted, and the NDA holder or patent owner sues the ANDA applicant for patent infringement as a result of notice of the paragraph IV certification." Based upon the FDA's statement, the Company believes that following the commencement of its anticipated infringement... (PR Newswire)
